References
- Landesman S H, Cherubin C E, Corrado M L. Gram-negative bacillary meningitis: new therapy and changing concepts. Arch Intern Med 1982; 142: 939–940
- Rahal J J, Simberkoff M S, Landesman S H. and The Metropolitan Meningitis Study Group. Prospective evaluation of moxalactam therapy for gram-negative bacillary meningitis. J Infect Dis 1984; 149: 562–567
- O'Callaghan C H, Morris A, Kirby S M, Shingler A H. Novel method for detection of β-lactamase by using a chromogenic cephalosporin substrate. Antimicrob Agents Chemother 1972; 1: 283–288
- The choice of antimicrobial drugs. Med Lett Drugs Ther 1986; 28: 33–40
- Svarva P L, Lyng R V, Mæland J A. Emergence of β-lactam multiresistant variants of gramnegative bacilli in the presence of cefotaxime. Scand J Infect Dis 1985; 17: 387–391
- Olson B, Weinstein R A, Nathan C, Kabins S A. Broad spectrum β-lactam resistance in Enterobacter: Emergence during treatment and mechanisms of resistance. J Antimicrob Chemother 1983; 11: 299–310
- Eng R HK, Cherubin C, Smith S M, Buccini F. Examination of gram-negative bacilli from meningitis patients who failed or relapsed on moxalactam therapy. Antimicrob Agents Chemother 1984; 26: 850–856
- Sanders C C, Sanders W E, Jr. Emergence of resistance during therapy with the newer β-lactam antibiotics: role of inducible β-lactamases and implications for the future. Rev Infect Dis 1983; 5: 639–648
- Werner V, Sanders C C, Sanders W E, Jr., Goering R V. Role of β-lactamases and outer membrane proteins in multiple β-lactam resistance of Enterobacter cloacae. Antimicrob Agents Chemother 1985; 27: 455–459
- Levitz R E, Quintiliari R. Trimethoprim-sulfamethoxazole for bacterial meningitis. Ann Intern Med 1984; 100: 881–890